Introduction {#Sec1}
============

Peritoneal dialysis (PD) is one of the common renal replacement therapies for patients with end-stage renal disease (ESRD). The break-in period refers to the time between catheter insertion and routine catheter use. The treatment strategy used during the break-in period allows patients to adapt to the dialysis process. Patients usually undergo the PD break-in period of 2 weeks after catheterization \[[@CR1]\]. However, there are some patients needing an urgent-start PD immediately after PD catheter insertion. In order to reduce the incidences of mechanical complications caused by urgent-start of PD treatment such as peritoneal fluid leakage and hernia, an incremental initiation of continuous ambulatory peritoneal dialysis (CAPD) is traditionally applied over the break-in period by gradual introduction of dialysate exchanges from a small-dose to full-dose therapy (e.g., from 500--800 to 2000 mL each session) \[[@CR2]\]. Considering insufficient volume of dialysate exchanges, some researchers advocate intermittent PD (IPD) by increased times of dialysis fluid exchange \[[@CR3]\]. However, frequent dialysis exchange will not only increase the workload of healthcare workers, but also incur increased risk of infection.

With the advent of automatic peritoneal dialysis (APD) machine, PD can be carried out automatically by filling and draining the dialysate, and fewer connections and disconnections could potentially reduce the risk of peritonitis \[[@CR4]\]. In recent years, APD has been reported to be used for urgent-start PD treatment \[[@CR5]--[@CR7]\]. However, no consensus has been reached on the optimal PD mode during the break-in period, especially for the dose of PD.

In this study, a total of 96 ESRD patients who treated with urgent-start PD after catheterization were retrospectively analyzed. The aim of the study was to evaluate the different PD modes during the break-in period and to establish an appropriate treatment strategy for patients with urgent-start PD.

Materials and methods {#Sec2}
=====================

Participants {#Sec3}
------------

The ESRD patients who treated with urgent-start PD after catheterization in the Second Hospital of Jilin University from October 2013 to July 2017 were enrolled. Inclusion criteria included (1) age between 18 and 85 years old, male or female; (2) diagnosis of ESRD; (3) urgent-start PD on 1--3 days after catheterization; (4) nine-day treatment during break-in period. The following criteria were used to exclude patients from this study: acute renal failure; hemodialysis during the break-in period; hemorrhagic complications after catheterization; systemic co-morbidities such as malignancies, systemic infection, cirrhosis and congestive heart failure.

PD prescription {#Sec4}
---------------

All patients received the placement of polyester double-cuff straight Tenckhoff catheter by experienced surgeons in accordance with standard operating procedures. The implantation of PD catheter was performed by an open surgery. Briefly, a left paramedian incision was made at 9--13 cm above the pubic symphysis. Subcutaneous tissue was carefully detached to reach anterior sheath of the rectus muscle, and the anterior rectus sheath was incised (2--4 cm in length). And then the posterior rectus abdominis sheath was opened and cut to expose the peritoneum after blunt detachment. The peritoneum was then incised to create a small opening. With the help of a guide wire, the PD catheter was placed into the peritoneal cavity of the abdomen. All operations were performed by the same team of clinicians.

Patients were divided into three groups according to PD prescription during the break-in period, namely APD group (*n* = 42, APD for 9 days), APD--CAPD group (*n* = 28, APD for 6 days followed by CAPD for 3 days) and CAPD group (*n* = 26, incremental CAPD for 9 days). The regimen in the APD group included 9 fill/drain cycles of 650 mL over 48 min and one long overnight dwell for the first 3 days, 8 cycles of 1000 mL over 48 min and a dwell overnight during 4--6 days, and 6 cycles of 1500 mL over 48 min and a dwell overnight during 7--9 days. The regimens in the CAPD were 4 cycles of 500--800 mL over 3--4 h and dwell overnight for the first 3 days, 4 cycles of 1000 mL over 3--4 h and dwell overnight during 4--6 days, and 4 cycles of 1500 mL over 4 h and dwell overnight during 7--9 days. Patients in the APD--CAPD group were treated with APD regimen that was consistent with the APD group for the first 6 days, and CAPD during 7--9 days (4 cycles of 1500 mL over 4 h and dwell overnight).

Data collection {#Sec5}
---------------

The laboratory data, blood pressure, estimated glomerular filtration rate (eGFR), PD complications (PD-associated peritonitis, catheter-related infection, mechanical complications, etc.) were collected before and after the break-in period as well as at a month after the initiation of PD treatment. eGFR was calculated by CKD-EPI formula among patients who initiated PD; while for the patients who underwent PD, residual kidney GFR was estimated by the formula: (renal urea clearance rate + renal creatinine clearance rate)/2. A routine peritoneal equilibration test was performed at 1 month after catheterization.

Statistical analysis {#Sec6}
--------------------

The SPSS 19.0 statistical software package was used for statistical analysis. Continuous data were expressed as mean ± standard deviation (SD), and categorical data were expressed as absolute value and percentage. Continuous data were analyzed by the *t* test and analysis of variance with least significant difference test to evaluate differences among groups. Numeration data were analyzed with Chi-square test. *P* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Demographic and baseline characteristics of subjects {#Sec8}
----------------------------------------------------

A total of 96 ESRD patients who treated with urgent-start PD after catheterization were enrolled, including 50 (52.1%) males and 46 (47.9%) females, with an average age of 53.91 ± 1.54 (range 22--77) years old. There were no significant differences in gender distribution, age, blood pressure, proportion of diabetic nephropathy, biochemical indicators, and the use of medication for hypertension control, improving anemia and decreasing phosphate levels during the break-in period among the three groups (all *P* \> 0.05, Table [1](#Tab1){ref-type="table"}).Table 1Demographic and baseline characteristics of the subjectsAPD group (*n* = 42)APD--CAPD group (*n* = 28)CAPD group (*n* = 26)*P* value^†^Male, *n* (%)23 (54.8)14 (50.0)13 (50.0)0.898Age (years)51.88 ± 13.4955.00 ± 16.6155.74 ± 9.770.527Systolic blood pressure (mmHg)152.70 ± 16.90147.70 ± 18.00154.90 ± 20.890.418Diabetic nephropathy, *n* (%)15 (35.7)12 (42.8)8 (30.8)0.648Medication, *n* (%) Antihypertensive agents30 (71.4)22 (67.9)19 (73.1)0.795 Anemia-improving agents\*31 (73.8)22 (78.6)18 (69.2)0.737 Phosphorus-reducing agents22 (52.4)14 (50.0)15 (57.7)0.845Blood urea nitrogen (mmol/L)25.05 ± 8.9722.66 ± 9.1221.29 ± 7.170.195Creatinine (umol/L)853.40 ± 233.15811.10 ± 225.99824.30 ± 279.700.761Uric acid (umol/L)445.80 ± 108.00437.70 ± 126.78434.60 ± 88.640.907iPTH (pg/mL)418.90 ± 193.32447.90 ± 165.40445.90 ± 228.640.845Serum potassium (mmol/L)4.72 ± 0.774.60 ± 0.724.63 ± 0.750.803Serum calcium (mmol/L)2.02 ± 0.272.08 ± 0.232.11 ± 0.250.323Serum phosphorus (mmol/L)1.99 ± 0.731.89 ± 0.591.92 ± 0.710.805Serum sodium (mmol/L)140.20 ± 2.95140.10 ± 3.53140.90 ± 5.060.735CO2-CP (mmol/L)22.24 ± 2.3921.73 ± 3.0722.58 ± 3.040.532Albumin (g/L)35.13 ± 6.1233.87 ± 5.4432.93 ± 5.520.298Pre-albumin (mg/L)301.20 ± 76.53291.70 ± 52.59289.20 ± 75.210.751Total protein (g/L)65.06 ± 11.1965.56 ± 9.1864.15 ± 8.710.872Fasting plasma glucose (mmol/L5.61 ± 1.555.65 ± 1.785.57 ± 1.060.984Hemoglobin (g/L)80.69 ± 13.4382.54 ± 12.4681.35 ± 14.670.855eGFR (mL/min/1.73 m^2^)^\#^5.71 ± 2.105.52 ± 1.696.40 ± 2.290.312Urine volume (mL)1352.00 ± 303.571381.00 ± 446.441581.00 ± 545.540.149APD, automatic peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CO2-CP, carbon dioxide combining power; eGFR, estimated glomerular filtration rate; iPTH, intact parathyroid hormone\*Included erythropoiesis-stimulating agents, iron, folic acid and vitamin B12^\#^CKD-EPI formula was used to calculate eGFR^†^The *P* values were compared among the three groups by one-way ANOVA

Comparison of changes in parameters among groups after treatment during the break-in period {#Sec9}
-------------------------------------------------------------------------------------------

APD and APD--CAPD were able to clear small-molecule toxins (creatinine, blood urea nitrogen and uric acid) and electrolytes (potassium and phosphorus), by comparison of biochemical indicators before and after treatments (*P* \< 0.05, Table [2](#Tab2){ref-type="table"}). For CAPD, only clearance of blood urea nitrogen and potassium was achieved to a statistical significance level (*P* \< 0.05).Table 2Parameters after treatment over the break-in periodAPD group (*n* = 42)*P*APD--CAPD group (*n* = 28)*P*CAPD group (*n* = 26)*P*Toxins Blood urea nitrogen (mmol/L)14.41 ± 5.680.00013.51 ± 4.030.00016.40 ± 5.430.008 Creatinine (umol/L)657.80 ± 193.710.000627.30 ± 154.410.001711.00 ± 258.940.136 Uric acid (umol/L)370.60 ± 73.480.000357.80 ± 107.320.014404.50 ± 87.200.223Electrolytes Serum potassium (mmol/L)3.80 ± 0.500.0003.75 ± 0.510.0004.17 ± 0.510.012 Serum calcium (mmol/L)2.12 ± 0.250.0692.17 ± 0.250.1542.23 ± 0.310.132 Serum phosphorus (mmol/L)1.43 ± 0.380.0001.27 ± 0.270.0001.68 ± 0.470.160 Serum sodium (mmol/L)139.00 ± 3.750.094141.20 ± 3.500.277141.50 ± 3.340.589 CO2-CP (mmol/L)24.51 ± 2.700.00024.93 ± 3.750.00124.48 ± 2.010.010Nutritional indicators Albumin (g/L)29.81 ± 4.850.00031.33 ± 5.320.08332.32 ± 5.380.691 Pre-albumin (mg/L)268.60 ± 87.230.072299.60 ± 107.410.728302.20 ± 83.050.556 Total protein (g/L)58.30 ± 8.700.00361.72 ± 8.830.11760.19 ± 7.180.080Others FPG (mmol/L)5.32 ± 0.870.3025.46 ± 0.920.6225.58 ± 1.270.983 Hemoglobin (g/L)81.26 ± 15.340.85683.00 ± 11.440.88585.19 ± 13.860.336APD, automatic peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CO2-CP, carbon dioxide combining power; FPG, fasting plasma glucose. *t* test for comparing the value before PD and after break-in period, *P* \< 0.05

We next compared the efficacy of three PD modes in the break-in period (Table [3](#Tab3){ref-type="table"}). APD and APD--CAPD were superior to CAPD in clearance of serum creatinine, blood urea nitrogen and uric acid (*P* \< 0.05). In addition, APD and APD--CAPD were more potent in reduction of potassium and phosphorus than CAPD only (*P* \< 0.05). However, there was no significant difference in calcium, sodium and carbon dioxide combining power changes after treatment among groups (*P* \> 0.05). APD led to a significant decline in albumin and pre-albumin, as compared with APD--CAPD and CAPD (*P* \< 0.05). There was no significant difference in albumin and pre-albumin reduction between the APD--CAPD group and CAPD group (*P* \> 0.05).Table 3Comparison of changes in parameters after treatment over the break-in period among the three groupsAPD group (*n* = 42)APD--CAPD group (*n* = 28)CAPD group (*n* = 26)*P* ^a^*P* ^b^*P* ^c^Toxins Blood urea nitrogen (mmol/L)− 10.64 ± 6.66− 9.15 ± 6.78− 4.89 ± 3.570.3670.0000.006 Creatinine (umol/L)− 195.50 ± 114.84− 183.80 ± 161.41− 113.50 ± 61.730.7230.0420.001 Uric acid (umol/L)− 75.14 ± 67.62− 79.86 ± 56.42− 30.12 ± 56.830.7620.0060.002Electrolytes Serum potassium (mmol/L)− 0.91 ± 0.78− 0.86 ± 0.72− 0.46 ± 0.530.7630.0120.027 Serum calcium (mmol/L)0.11 ± 0.320.09 ± 0.310.12 ± 0.230.8790.8600.743 Serum phosphorus (mmol/L)− 0.57 ± 0.61− 0.61 ± 0.63− 0.24 ± 0.380.7520.0170.011 Serum sodium (mmol/L)− 1.25 ± 4.831.03 ± 4.630.65 ± 3.010.0530.0780.720 CO2-CP (mmol/L)2.27 ± 2.953.20 ± 3.871.91 ± 3.920.2610.6650.968Nutritional indicators Albumin (g/L)− 5.30 ± 4.70− 2.54 ± 4.37− 0.60 ± 5.120.0160.0000.140 Pre-albumin (mg/L)− 32.64 ± 66.397.89 ± 90.4313.04 ± 80.970.0350.0140.827 Total protein (g/L)− 6.76 ± 5.78− 3.87 ± 6.66− 3.96 ± 4.980.0590.0450. 958Others FPG (mmol/L)− 0.28 ± 1.62− 0.19 ± 1.710.01 ± 1.560.8130.4690.665 Hemoglobin (g/L)0.57 ± 10.500.46 ± 13.033.85 ± 7.550.9700.1720.253APD, automatic peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CO2-CP, carbon dioxide combining power^a^Comparison between the APD group and APD--CAPD group; ^b^comparison between the APD group and CAPD group; ^c^comparison between the APD--CAPD group and CAPD group

Comparison of PD-related complications of three PD modes during the break-in period {#Sec10}
-----------------------------------------------------------------------------------

There were no differences in the incidences of PD-related complications among three groups, including catheter migration, PD fluid leakage, abdominal pain, abdominal distention, catheter obstruction, PD- or catheter-related peritonitis during the break-in period (all *P* \> 0.05, Table [4](#Tab4){ref-type="table"}).Table 4Comparison of PD-related complications over the break-in periodComplications, *n* (%)APD group (*n* = 42)APD--CAPD group (*n* = 28)CAPD group (*n* = 26)Total (*n* = 98)*P* valueCatheter migration4 (9.5)3 (10.7)2 (7.7)9 (9.2)0.929PD fluid leakage2 (4.8)1 (3.6)1 (3.8)4 (4.1)0.966Abdominal pain3 (7.1)3 (10.7)2 (7.7)8 (8.2)0.861Abdominal distention2 (4.8)1 (3.6)1 (3.8)4 (4.1)0.966Catheter obstruction1 (2.4)1 (3.6)1 (3.8)3 (3.1)0.932PD-related peritonitis1 (2.4)01 (3.8)2 (2.0)0.603Catheter-related peritonitis1 (2.4)1 (3.6)2 (7.7)4 (4.1)0.557PD, peritoneal dialysis

Comparison of changes in parameters among groups at a month after treatment {#Sec11}
---------------------------------------------------------------------------

All the three types of PD models were able to clear toxins (creatinine, blood urea nitrogen, uric acid and iPTH) and improve electrolyte disorders (potassium, calcium, phosphorus and CO2-CP), by comparison of biochemical indicators before and after treatment (*P* \< 0.05, Table [5](#Tab5){ref-type="table"}).Table 5Parameters at a month after treatmentAPD group (*n* = 42)*P*APD--CAPD group (*n* = 28)*P*CAPD group (*n* = 26)*P*Toxins Blood urea nitrogen (mmol/L)14.07 ± 4.760.00013.42 ± 4.790.00111.54 ± 3.710.000 Creatinine (umol/L)694.40 ± 186.750.003610.20 ± 185.660.004638.10 ± 211.030.010 Uric acid (umol/L)372.00 ± 79.120.002358.30 ± 113.980.045382.50 ± 82.380.035 iPTH (pg/mL)321.20 ± 180.910.044306.3 ± 138.850.014305.3 ± 159.740.017Electrolytes Serum potassium (mmol/L)4.22 ± 0.630.0054.15 ± 0.460.0294.39 ± 0.590.210 Serum calcium (mmol/L)2.25 ± 0.270.0002.41 ± 0.230.0002.30 ± 0.170.002 Serum phosphorus (mmol/L)1.58 ± 0.390.0061.42 ± 0.400.0081.46 ± 0.430.007 Serum sodium (mmol/L)142.10 ± 3.150.011143.70 ± 2.770.001142.30 ± 2.830.209 CO2-CP (mmol/L)25.37 ± 2.680.00024.66 ± 2.500.00225.52 ± 3.100.001Nutritional indicators Albumin (g/L)38.12 ± 6.050.04238.75 ± 3.970.00337.88 ± 3.330.000 Pre-albumin (mg/L)375.40 ± 95.850.001361.80 ± 59.670.000339.40 ± 105.900.056 Total protein (g/L)67.96 ± 7.410.21370.64 ± 7.270.06568.50 ± 5.860.043Others FPG (mmol/L)6.25 ± 1.870.1117.34 ± 3.380.0356.91 ± 2.250.009 Hemoglobin (g/L)107.30 ± 15.620.000112.10 ± 11.940.000110.20 ± 18.980.000 GFR (mL/min/1.73 m^2^)^\#^4.08 ± 2.030.0034.08 ± 1.700.0055.26 ± 2.370.114 Urine volume (mL)1190.00 ± 531.330.1531308.00 ± 494.240.5941376.00 ± 420.600.181APD, automatic peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CO2-CP, carbon dioxide combining power; FPG, fasting plasma glucose; GFR, glomerular filtration rate. *t* test for comparing the value before PD and after break-in period, *P* \< 0.05^\#^Residual kidney GFR was estimated by the formula: (renal urea clearance rate + renal creatinine clearance rate)/2

There were no significant differences in all tested biochemical parameters among groups at 1 month after treatment (all *P* \> 0.05, Table [6](#Tab6){ref-type="table"}).Table 6Comparison of changes in parameters among groups at a month after treatmentAPD group (*n* = 42)APD--CAPD group (*n* = 28)CAPD group (*n* = 26)*P* valueToxins Blood urea nitrogen (mmol/L)− 10.13 ± 7.98− 8.15 ± 10.45− 8.65 ± 7.090.689 Creatinine (umol/L)− 172.50 ± 100.23− 195.60 ± 142.75− 159.90 ± 177.340.731 Uric acid (umol/L)− 61.77 ± 81.87− 47.13 ± 99.23− 50.84 ± 74.940.817 iPTH (pg/ml)− 97.73 ± 159.48− 141.40 ± 82.40− 140.70 ± 124.940.409Electrolytes Serum potassium (mmol/L)− 0.53 ± 0.93− 0.34 ± 0.870.01 ± 0.650.059 Serum calcium (mmol/L)0.26 ± 0.240.30 ± 0.260.19 ± 0.310.434 Serum phosphorus (mmol/L)− 0.59 ± 0.51− 0.73 ± 0.63− 0.60 ± 0.700.728 Serum sodium (mmol/L)1.71 ± 3.413.30 ± 5.141.32 ± 4.780.343 CO2-CP (mmol/L)2.57 ± 3.642.49 ± 2.663.12 ± 4.500.823Nutritional indicators Albumin (g/L)3.37 ± 4.544.21 ± 4.114.89 ± 4.500.443 Pre-albumin (mg/L)62.33 ± 97.0645.44 ± 81.6243.00 ± 74.100.669 Total protein (g/L)3.27 ± 7.416.02 ± 4.326.38 ± 6.590.169Others Fasting plasma glucose (mmol/L)0.45 ± 2.671.72 ± 2.301.42 ± 1.770.142 Hemoglobin (g/L)26.26 ± 14.3332.47 ± 14.0828.43 ± 21.580.475 GFR (mL/min/1.73 m^2^)− 1.63 ± 1.63− 1.44 ± 1.60− 1.14 ± 2.650.679 Urine volume (mL)− 161.70 ± 528.45− 72.92 ± 469.64− 195.50 ± 550.740.706CO2-CP, carbon dioxide combining power; iPTH, intact parathyroid hormone; GFR, glomerular filtration rate^\#^Residual kidney GFR was estimated by the formula: (renal urea clearance rate + renal creatinine clearance rate)/2

Peritoneal equilibration tests for three PD modes {#Sec12}
-------------------------------------------------

There were no significant differences in the ratios of number of patients with high peritoneal transport to those with low transport among groups (*P* \> 0.05, Table [7](#Tab7){ref-type="table"}).Table 7Results of peritoneal equilibration tests for three PD modesAPD groupAPD--CAPD groupCAPD group*P*High transport/low transport (*n*/*n*)^a^24/1815/1315/110.943^a^High transport: high transport + high average transport; low transport: low transport + low average transport

Discussion {#Sec13}
==========

Peritoneal dialysis is an effective method of removing of fluid and various sizes of solute molecules. Our results showed that APD and APD--CAPD were able to equivalently clear small-molecule toxins, which was superior to CAPD alone. The results were consistent with other studies \[[@CR8]--[@CR10]\]. The reasons were probably because the former was related to larger volume of dialysate exchanges, shorter retention time and more cycles. However, some researchers denied the possibility of improved clearance of small-molecule toxins by increased retention duration, which on the contrary would lead to the retention of toxic components in dialysate and decreased solute clearance rate \[[@CR11]\]. In this study, high dose of APD yielded a superior small-molecule clearance rate, but similar intermediate- and large-molecule clearance rates in comparison with low dose of CAPD during the break-in period. These findings were similar to the previous results \[[@CR10]\]. However, confirmation of these findings will require further investigation with a larger sample size.

Evidence has shown that the mortality rate in PD patients can be reduced by 11--47% with every increase in GFR of 5--10 L/min/1.73 m^2^ \[[@CR12]\]. Preservation of residual renal function (RRF) at the greatest extent should be considered when selecting a HD mode. By observing 505 CAPD and 78 APD patients, Michels et al. \[[@CR13]\] found that the risk of complete loss of renal function within the first years in APD group was twofold higher than that of CAPD group. The unfavorable outcome in RRF caused by APD may be explained by a large amount of ultrafiltration in a short period of time that can lead to renal ischemia. However, in a multicenter controlled study, no significant difference in RRF decline was found between APD and CAPD treatment during 90 days after the start of dialysis treatment \[[@CR14]\]. Similarly, our results did not reveal a significant difference in GFR values among groups at 1 month after PD treatment. Efforts should be made to clarify the impact of different PD modes on the long-term RRF.

PD patients are at high risk of hypokalemia, with an incidence rate of 15--60% \[[@CR15]\]. For a patient who undergoes a standard CAPD (8 L/day), approximate 40 mEq of potassium ion is removed daily, and the clearance rate is about 7--26 mL/min \[[@CR16]\]. A study revealed increased probability of hypokalemia occurrence in patients who underwent APD at a weekly dialysis dose of 90 L or more \[[@CR17]\]. In the present study, APD and APD--CAPD treatment led to more remarkable decline in potassium than CAPD did during the break-in period, probably due to short retention time and larger volume of dialysate exchanges in APD group.

A number of studies showed that the occurrence of hypokalemia and malnutrition are closely related \[[@CR17]--[@CR19]\]. Malnutrition is one of the most common complications of PD patients. According to the latest study, 67.84% of patients with PD have mild to moderate malnutrition and 7.07% have severe malnutrition \[[@CR20]\]. A number of studies show that malnutrition is an important indicator of predicting the mortality of PD patients \[[@CR21], [@CR22]\]. Although APD achieves satisfactory clearance of small-molecule toxins, it leads to higher protein losses than CAPD due to multiple nighttime exchanges \[[@CR8]\]. Our results supported the evidence that APD resulted in a more severe reduction of albumin and pre-albumin than CAPD during the break-in period. Interestingly, the levels of albumin and pre-albumin were not different among the three groups at a month after treatment. This probably is because APD enabled a potent clearance of toxins, which improved the appetite and digestive capacity of the patients, thereby promoting protein intake and absorption. Thus, APD--CAPD seemed to be an optimal PD mode during the break-in period, as it exhibited a high capacity of uremic toxin clearance and did not increase the risk of malnutrition as well.

Peritonitis is a serious complication of PD patients, leading to technical failure rate of up to 78% \[[@CR23]\], rehospitalization rate of 13.5% \[[@CR24]\] and PD peritonitis-related mortality rate of 15.2% \[[@CR25]\]. The APD mode reduces the number of daily connections and disconnections and the chance of manual operation, thus decreasing the incidence of peritonitis \[[@CR26]\]. A meta-analysis demonstrated that the incidence of peritonitis in APD group was decreased by 46% as compared with CAPD group \[[@CR27]\]. In this study, the incidences of PD- and catheter-related peritonitis were 4.8, 3.6 and 11.5% in the APD group, APD--CAPD group and CAPD group, respectively, suggesting the advantage of APD over CAPD as reduced incidence of peritonitis.

Patients usually undergo a PD break-in period of 2 weeks after catheterization to improve the long-term life expectancy of the catheter and minimize the mechanical complications \[[@CR28]\]. The incidence of catheter displacement is reported as high as 12.7--35% \[[@CR29]\]. Immediate start of PD leads to an increased incidence of peritoneal fluid leakage (7.7%) \[[@CR7]\]. In this study, the overall incidence rates of catheter displacement and PD fluid leakage were 9.4% (9/96) and 4.2% (4/96), revealing that urgent-start PD did not increase the occurrence of catheter displacement as well as peritoneal fluid leakage, which was consistent with previous study \[[@CR5]\]. The low rates of mechanical complications in this study probably attributed to the incremental initiation of PD treatment which enabled a gradual increase in intra-abdominal pressure of patients.

This study was a single-center, retrospective cohort study with a relatively small sample size. Further studies with larger sample size are needed to confirm these findings.

In conclusion, compared with the traditional incremental CAPD, APD mode could effectively remove uremic toxins, correct electrolyte imbalance, while did not increase the incidence of early complications during the break-in period. A PD strategy consisting 6 days of APD and 3 days of CAPD showed a great advantage in preventing excessive protein loss. Thus, a combination of APD and CAPD regimens is recommend for patients with urgent-start PD during the break-in period.

APD

:   Automatic peritoneal dialysis

CAPD

:   Continuous ambulatory peritoneal dialysis

eGFR

:   Estimated glomerular filtration rate

ESRD

:   End-stage renal disease

IPD

:   Intermittent peritoneal dialysis

PD

:   Peritoneal dialysis

RRF

:   Residual renal function

SEM

:   Standard error of mean
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